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Evidence that Monastrol
Is an Allosteric Inhibitor
of the Mitotic Kinesin Eg5
inhibitors against the mitotic kinesin Eg5 have been re-
ported [4, 5] (Feng, Y., Kapoor, T.M., Mayer, T.U., Maliga,
Z., and Mitchison, T.J., patent pending) allowing the use
of cell-permeable small molecules to specifically target
Eg5 function in vivo.
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250 Longwood Avenue two poles of the mitotic spindle apart, although exactly
Boston, Massachusetts 02115 how this force acts is controversial [6, 9, 11, 30]. In
4 Laboratory of Chemistry and Cell Biology previous experiments where Eg5 is mislocalized or in-
Rockefeller University hibited in vivo [7, 3], minus-end-directed motors from
1230 York Avenue, Box 202 the kinesin and dynein family cause the spindle poles
New York, New York 10021 to collapse together, resulting in a mono-aster [8, 9].
Treatment of tissue culture cells or mitotic cell extracts
with monastrol also results in this characteristic “mono-
astral” spindle phenotype [4]. However, it is importantSummary
to understand the mechanism of Eg5 inhibition by mon-
astrol in order to interpret the resulting mono-astral phe-Monastrol, a cell-permeable inhibitor of the kinesin
notype and to understand the function of Eg5 in vivo.Eg5, has been used to probe the dynamic organization
For example, Eg5 blocked in a filament-unbound stateof the mitotic spindle. The mechanism by which mon-
would mimic a loss-of-function phenotype, whereas Eg5astrol inhibits Eg5 function is unknown. We found that
blocked in a filament-bound state could interfere withmonastrol inhibits both the basal and the microtubule-
the action of other motors indirectly.stimulated ATPase activity of the Eg5 motor domain.
The N-terminal motor domain of Eg5 shares structuralUnlike many ATPase inhibitors, monastrol does not
and sequence homology with other kinesins [10] and iscompete with ATP binding to Eg5. Monastrol appears
responsible for microtubule binding and ATP hydrolysis.to inhibit microtubule-stimulated ADP release from
Eg5 but does not compete with microtubule binding, The stalk region abutting the motor domain mediates
suggesting that monastrol binds a novel allosteric site oligomerization by forming a coiled-coil. Full-length Eg5
in the motor domain. Finally, we established that (S)- can transport microtubules in vitro [11] and is thought
monastrol, as compared to the (R)-enantiomer, is a to exist as a homotetrameric complex in the mitotic
more potent inhibitor of Eg5 activity in vitro and in spindle [9, 30]. Shorter N-terminal fragments of Eg5 con-
vivo. Future structural studies should help in designing taining substantial putative coiled-coil sequence still
more potent Eg5 inhibitors for possible use as antican- support microtubule gliding in vitro with velocities com-
cer drugs and cell biological reagents. parable to the full-length protein [4]. The N-terminal Eg5
motor domain alone is not expected to transport mi-
crotubules but is expected to demonstrate the microtu-Introduction
bule-stimulated ATPase activity characteristic of other
kinesins [2]. Monastrol has been reported to inhibit mi-Motor proteins from the kinesin, dynein, and myosin
crotubule gliding by a truncated, dimeric Eg5 proteinfamilies are involved in intracellular transport, mitotic
construct in vitro [4]. Identifying a minimal region ofspindle assembly, chromosome segregation, cell divi-
Eg5 inhibited by monastrol would be a useful model tosion, and cell motility [1, 2]. Numerous kinesin and myo-
sin motor proteins are expressed in a given cell type, characterize the biochemical mechanism of inhibition
making it difficult to identify a unique function for a and to understand how larger assemblies of Eg5 are
particular motor protein. Antibodies [3] can be used to inhibited. Furthermore, a smaller Eg5 fragment would
inhibit the activity of motor proteins; however, they are facilitate identification of the monastrol binding site by
difficult to introduce into cells and may take a long time X-ray crystallography.
to act, limiting the usefulness of these tools in biochemi- Like many enzyme inhibitors, monastrol might be sub-
cal and live imaging studies. strate competitive, inhibiting the ATP hydrolysis cycle
Small molecules are useful reagents to dissect protein of Eg5 by directly competing with ATP [27, 28, 31] or
function because their biological effects can often be microtubule binding. Alternatively, monastrol might in-
interpreted in light of a discrete biochemical mechanism. hibit the motor domain allosterically, either by inhibiting
However, previous small molecules used to inhibit motor ATP hydrolysis or by uncoupling partner head interac-
proteins, such as ortho-vanadate or nonhydrolyzable tions to inhibit motor but not ATPase activity [12, 13,
ATP analogs, display poor specificity and are not cell 29]. We used a combination of steady-state enzyme
permeable. Recently, several classes of small-molecule kinetics and equilibrium binding experiments to under-
stand the mechanism of Eg5 inhibition by monastrol in
vitro.5 Correspondence: maliga@fas.harvard.edu
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Figure 2. Monastrol Does Not Compete with ATP Binding
(A) The ATPase activity of 38 nM Eg5-367H at 200 nM microtubules
as a function of ATP concentration in the presence of 0 M (cross),
6.2 M (diamond), 13 M (triangle), 25 M (square), 50 M (circle)
monastrol. Each data point is the average of three independent
experiments. Enzyme velocities at the same monastrol concentra-
tion were fit to the Michaelis-Menten equation to obtain Vmax and
KmATP.
(B) To demonstrate the expected behavior for an ATP-competitive
inhibitor, the rate of ATP hydrolysis by 38 nM Eg5-367H at 200 nM
microtubules was measured as a function of ATP concentration in
the presence of 0 M (cross), 10 M (diamond), 20 M (triangle),
40 M (square), and 80M (circle) AMP-PNP. Each data point is the
average of three independent experiments. Enzyme velocities atFigure 1. Monastrol Inhibits Basal and Microtubule-Stimulated ATP
the same AMP-PNP concentration were fit to the Michaelis-MentenHydrolysis by the Eg5 Motor Domain
equation to obtain Vmax and KmATP.
(A) The chemical structures of monastrol and para-monastrol, an
inactive derivative.
(B) The rate of ATP hydrolysis by 500 nM Eg5-367H was measured
in reaction buffer containing 1 mM ATP as a function of monastrol 437H) amino acids, respectively, contained progres-
() or para-monastrol () concentration. Each data point is the sively more of the neck linker and stalk region. Surpris-
average of three independent trials. The ATPase activity, Vmax, of ingly, all three constructs behaved as monomers by
Eg5-367H was 0.08  0.01 s1. Monastrol completely inhibited ATP
gel filtration (data not shown) and analytical equilibriumhydrolysis with an IC50 of 6.3  0.5 M.
sedimentation (S. Gilbert, personal communication), de-(C) The rate of microtubule-stimulated ATP hydrolysis by 40 nM Eg-
spite substantial predicted coiled-coil sequence in the367H was measured in the presence of 500 nM microtubules, 1 mM
ATP, and monastrol () or para-monastrol (). Each data point is 437H construct. All three constructs displayed microtu-
the average of three independent trials. Monastrol inhibited ATP bule-stimulated ATPase activity, although Eg5-437H is
hydrolysis by 87  2% with an IC50 of 34  3 M. the only construct that translocates microtubules in vitro
(T. Kapoor, personal communication). At saturating ATP
and microtubule concentrations, Eg5-367H exhibited aResults
higher rate of steady-state ATP hydrolysis (20 s1) than
the longer Eg5-405H (2.3 s1) and Eg5-437H (2.7 s1)Monastrol Inhibits ATP Hydrolysis by the Eg5
Motor Domain constructs (data not shown). These results are consis-
tent with those obtained for conventional kinesin [14].To identify the minimal Eg5 fragment that could be inhib-
ited by monastrol, we generated three C terminally His6- We measured the rate of ATP hydrolysis by Eg5 in
the presence of increasing concentrations of monastroltagged Eg5 constructs. The shortest construct, Eg5-
367H, contained the N-terminal 367 amino acids of Eg5, or the control compound para-monastrol (Figure 1A).
Monastrol completely inhibits the basal ATPase activitythe minimal motor domain. The two longer constructs,
encoding the N-terminal 405 (Eg5-405H) and 437 (Eg5- of Eg5-367H with an IC50 of 6.1 M, whereas para-mon-
Mechanism of Eg5 Inhibition by Monastrol
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Figure 3. Monastrol Binds to the Eg5 Motor
Domain in a Complex with ADP
(A) The fluorescence (ex, 280 nm; em, 420
nm) of a solution containing 142 nM Eg5-
367H and increasing concentrations of mant-
ADP was measured. Subtracting the fluores-
cence of mant-ADP alone revealed that Eg5
enhanced the fluorescence of mant-ADP with
an apparent Kd of 1.2  0.2 M. Each data
point is the average of three independent ex-
periments.
(B) The fluorescence of 200 nM Eg5-367H and
27 M mant-ADP was measured in the pres-
ence of increasing monastrol concentration.
Each data point is the average of three inde-
pendent experiments, representing the nor-
malized mant-ADP fluorescence in the pres-
ence of Eg5 corrected for the internal
absorbance of mant-ADP fluorescence by
monastrol in bulk solution. Monastrol de-
creased FRET from Eg5-367H to mant-ADP
with an IC50 of 5.2  0.5 M. Each data point
is the average of three independent experi-
ments.
(C) Direct binding of 6 M Eg5-367H to ADP
(solid bar) and monastrol (white bar) was
measured in buffer alone or combinations of
10 M microtubules and 50 M monastrol.
ADP binding was unchanged upon quantita-
tive binding of monastrol to Eg5. ADP binding
to Eg5 was decreased in the presence of 10
M microtubules or 10 M microtubules and
50 M monastrol.
astrol is a weak Eg5 inhibitor (Figure 1B). ATP hydrolysis hydrolyzable ATP analog, increased KmATP with a negli-
gible decrease in Vmax, as expected for an ATP-competi-by the longer Eg5 constructs was also inhibited by mon-
astrol (data not shown). We used the Eg5-367H con- tive inhibitor (Figure 2B). Our results suggest that
monastrol does not bind in the nucleotide binding site.struct for further experiments as a minimal model to
explore the inhibition of Eg5 by monastrol.
Monastrol Inhibits the Microtubule-Stimulated Monastrol Binds to a Complex of Eg5 and ADP
We used mant-labeled ADP as a spectroscopic reporterATPase Activity of Eg5
Microtubule-stimulated ATPase activity is a useful to measure equilibrium binding of ADP to the Eg5 motor
domain [15]. We observed a dramatic enhancement ofmodel for ATP hydrolysis by Eg5, demonstrating the
allosteric communication between the nucleotide and mant-ADP fluorescence, when excited by 280 nm wave-
length radiation, by Eg5 that is consistent with fluores-microtubule binding sites of the motor domain. We ex-
amined the effect of monastrol and para-monastrol on cence resonance energy transfer (FRET) from trypto-
phan 127 near the nucleotide binding pocket [10] toATP hydrolysis by Eg5 in the presence of saturating
microtubules. Monastrol but not para-monastrol inhib- the mant fluorophore. We interpreted the fluorescence
enhancement as binding of mant-ADP to the Eg5 motorited the microtubule-stimulated ATPase activity of Eg5
by 90% with an IC50 of 34 M (Figure 1C). domain with a Kd of 1.2 M (Figure 3A).
In the absence of microtubules, monastrol decreased
FRET between Eg5 and mant-ADP in a dose-dependentMonastrol Does Not Compete with ATP Binding
Since many kinase inhibitors target the ATP binding site manner with an IC50 of 5.3 M (Figure 3B). This result
offers two possible interpretations: monastrol causes[27, 28, 31], we tested whether monastrol competes with
ATP for Eg5 binding using steady-state enzyme kinetics. release of mant-ADP from Eg5, or monastrol binds to
an Eg5-mant-ADP complex and causes a decrease inWe measured the rate of microtubule-stimulated ATP
hydrolysis in the presence of varying concentrations FRET efficiency. We distinguished these two possibili-
ties by directly measuring the binding of monastrol andof ATP and monastrol and fit each set of data to the
Michaelis-Menten equation. An ATP-competitive inhibi- ADP to Eg5. Whereas microtubules induced ADP re-
lease, monastrol binding to Eg5 did not (Figure 3C).tor would be expected to increase KmATP while Vmax
remained constant. Instead, we found that monastrol Therefore, the spectroscopic change upon monastrol
binding likely reflects disruption of FRET by monastroldecreased both KmATP and Vmax, inconsistent with ATP
competition (Figure 2A). By contrast, AMP-PNP, a non- and not ADP release.
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sonal communication). We assumed Michaelis-Menten
kinetics for microtubule binding and ADP release to ex-
amine the effect of monastrol on this catalytic step of
the Eg5 catalytic cycle (Figure 6) by changes in K0.5MT
and Vmax. Graphs of 1/Vmax and K0.5MT/Vmax increased lin-
early as functions of monastrol concentration with dis-
tinct x-intercepts. A linear-mixed type model of inhibi-
tion described in Segel [17] indicates that extrapolation
of the linear fits yields x-intercepts for the 1/Vmax and
K0.5MT/Vmax that are the Kd of monastrol from the Eg5-
ADP (11 M) and microtubule-Eg5-ADP (120 M) inter-
mediates, respectively (Figure 4B). These results sug-
gest that monastrol binds the Eg5-ADP complex and
inhibits productive microtubule binding such that ADP
is not released (Figure 6).
The (S) Enantiomer of Monastrol Is a Potent Eg5
Inhibitor In Vitro and In Vivo
A recent publication describes the enantiomeric separa-
tion of racemic monastrol by chiral HPLC [18]. However,
the biochemical activity of the two enantiomers has not
been reported, and publications to date have used the
racemic mixture to inhibit Eg5 in vivo [4, 6, 20]. To estab-
lish if a particular enantiomer is a more potent Eg5 inhibi-
tor, we resolved the two enantiomers by chiral HPLC
and measured their ability to inhibit the ATPase activity
of the Eg5 motor domain. Both (R)- and (S)-monastrol
abolished basal Eg5 ATPase activity, with the (S)-enanti-
omer demonstrating a 15-fold higher potency (FigureFigure 4. Monastrol Does Not Compete with Microtubule Binding
5A). In the presence of microtubules, (S)-monastrol also(A) The ATPase activity of 38 nM Eg5-367H in the presence of 200
inhibits ATPase activity by 90%, with an IC50 of 22 M,M ATP was measured as a function of microtubule concentration
and 0 M (cross), 50 M (diamond), 100 M (triangle), 200 M roughly half that of the racemate (Figure 1C), whereas
(square), and 400 M (circle) monastrol. Each data point is the the (R)-enantiomer is only a weak inhibitor (Figure 5B).
average of three independent experiments. Enzyme velocities at The (S)-enantiomer of monastrol is therefore the more
the same monastrol concentration were fit to the Michaelis-Menten
potent inhibitor of Eg5 ATPase activity in vitro.equation to obtain Vmax and K0.5MT.
Inhibition of Eg5 activity is the reported mechanism(B) A linear fit was applied to a replot of 1/Vmax () and K0.5MT/
for mono-aster formation in tissue culture cells followingVmax () values derived from Figure 4A as a function of monastrol
concentration. Extrapolation of the lines resulted in x-intercepts of monastrol treatment [4, 6]. Therefore, (S)-monastrol is
11  4 M for 1/Vmax and 118  6 M for K0.5MT/Vmax. expected to induce mono-astral cell formation at a lower
drug concentration than the (R)-enantiomer. To test this
prediction, we incubated BS-C-1 green monkey kidneyMonastrol Does Not Compete
cells in a range of drug concentrations for (R)-monastrol,with Microtubule Binding
(S)-monastrol, and racemic para-monastrol. (S)-monas-The increased IC50 of monastrol in the presence of micro- trol induced the mono-asters at 12 M, whereas 110tubules suggested the microtubule binding site of Eg5
M of (R)-monastrol was required for the same effect[16] as a possible monastrol binding site. In addition,
(Figure 5C). Para-monastrol displayed no effect on cellsthe microtubule-dependent decrease in Eg5-monastrol
at 200 M (data not shown). Notably, we observed upbinding (Figure 3C) also indicates that monastrol either
to 20% mono-astral cells at 1 mM monastrol. However,directly competes with microtubule binding or that the
these concentrations also appeared to be toxic to cells,monastrol and microtubule binding sites communicate
resulting in a lower overall cell count (data not shown).by some indirect, conformational mechanism. To test
These results indicate that (S)-monastrol is the potentwhether monastrol is competitive with microtubules, we
Eg5 inhibitor in vivo and a more convenient biochemicalmeasured the ATPase activity of the Eg5 motor domain
and cell biological reagent to inhibit the function of Eg5at various monastrol and microtubule concentrations.
function.Monastrol caused a concentration-dependent increase
in K0.5MT but also a decrease in the Vmax (Figure 4A),
which is inconsistent with monastrol being a microtu- Discussion
bule-competitive inhibitor. Therefore, monastrol likely
inhibits ATPase activity by binding to a novel allosteric The ability to inhibit Eg5 function in the mitotic spindle
apparatus makes monastrol a useful cell biological re-site on the Eg5 motor domain.
As observed for other kinesin proteins, microtubule agent and potentially a therapeutic compound for use
as an antimitotic agent. We identified a minimal modelbinding of the Eg5-ADP complex induces the formation
of a complex that rapidly releases ADP (S. Gilbert, per- for Eg5 inhibition by monastrol to facilitate identification
Mechanism of Eg5 Inhibition by Monastrol
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Figure 5. The S-Enantiomer of Monastrol Is
a Potent Eg5 Inhibitor In Vitro and In Vivo
(A) ATPase hydrolysis by 500 nM Eg5-367H
was measured in buffer containing 1 mM ATP
and increasing concentrations of (R)-mon-
astrol () or (S)-monastrol (). Each data
point is the average of three independent ex-
periments, normalized to a velocity of 0.08
s1. The two enantiomers inhibited Eg5 with
IC50 of 1.7  0.2 for the (S)- and 32  8 M
for the (R)-enantiomer.
(B) Microtubule-stimulated ATP hydrolysis by
50 nM Eg5-367H was measured in buffer con-
taining 1 mM ATP, 1 M microtubules, and
increasing concentrations of (R)-monastrol
() or (S)-monastrol (). Each data point is the
average of three independent experiments,
normalized to a velocity of 12 s1. The (S)-
enantiomer inhibited Eg5 by 93  6% with
IC50 of 15  5 M.
(C) The percentage of BS-C-1 tissue culture
cells exhibiting a mono-astral mitotic arrest
phenotype following 6 hr incubation at a par-
ticular concentration of (S)-monastrol (solid
bar) or (R)-monastrol (white bar). A lower con-
centration of (S)-monastrol is required to in-
duce a certain percentage of mono-astral
cells than (R)-monastrol.
of the drug binding site by future X-ray crystallography. inhibitors, monastrol does not target the nucleotide
binding pocket of Eg5 [27]. Instead, monastrol binds aIn addition, we performed a series of experiments to
gain a more thorough biochemical understanding of Eg5 complex of Eg5 and ADP, an intermediate in the Eg5
catalytic cycle (Figure 6). Although microtubules antago-inhibition by monastrol.
We found that monastrol inhibits ATP hydrolysis by nize monastrol binding to Eg5 (Figure 3C), the drug does
not directly compete with microtubule binding to Eg5the motor domain both alone and in the presence of
microtubules. Remarkably, in contrast to most kinase (Figure 4A). These data from steady-state kinetics (Fig-
Figure 6. Model for Inhibition of Eg5 Motor
Domain by Monastrol
Proceeding around the catalytic cycle of the
Eg5 motor domain (clear oval): the microtu-
bule-bound Eg5 motor (bottom right) domain
binds ATP. Hydrolysis of ATP is followed by
microtubule release from the Eg5-ADP com-
plex (center left). Rebinding of the Eg5-ADP
complex (center reaction) to microtubules re-
sults in ADP release and a return to a nucleo-
tide-free Eg5-microtubule complex. In our
model of monastrol-bound Eg5 (gray oval),
monastrol binds to the microtubule-free Eg5-
ADP complex (top left) and also, with lower
affinity, to a microtubule-bound Eg5-ADP in-
termediate (top right) that does not proceed
toward ADP release.
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ure 4B) and equilibrium binding experiments (Figure 3C) ments exploring the inhibition by monastrol of full-length
Eg5 ATPase activity and motility will shed further lightsuggest that monastrol inhibits microtubule-stimulated
ADP release from Eg5 (Figure 6). These results also on the mechanism of Eg5 inhibition in vivo.
suggest that monastrol is the first small-molecule inhibi-
tor of a motor protein to act by an allosteric mechanism. Significance
Enzyme inhibitors that do not compete with substrate
binding are particularly useful for inhibiting a specific Monastrol is the first cell-permeable small molecule
member of a broad family of related proteins. The sub- that specifically targets a motor protein. It has been
strate binding sites are often structurally conserved a useful tool to examine the dynamics of spindle as-
within members of a protein family, requiring a bump- sembly in vivo and in vitro. Our studies defined the
hole approach for rational design of inhibitors to study motor domain as the minimal region of Eg5 that inter-
protein function in vivo [19, 20]. By contrast, allosteric acts with monastrol, indicating a target for high-through-
inhibitors of kinesin motor proteins do not have to com- put screening of chemical libraries and identification
pete with high cellular concentrations of ATP or high of the monastrol binding site by X-ray crystallography.
local concentrations of microtubules in the mitotic spin- Our results suggest that monastrol inhibits the motor
dle. In addition, allosteric inhibition of Eg5 by monastrol activity of Eg5 by inhibiting ATP hydrolysis through
may be useful to dissect the mechanochemical cycle of an allosteric mechanism. This suggests the intriguing
kinesin motor proteins. possibility of targeting other motor proteins with spec-
Enantiomerically pure (S)-monastrol is a more potent ifc allosteric small-molecule inhibitors. Finally, we dis-
Eg5 inhibitor than the (R)-enantiomer both in vitro and in covered that (S)-monastrol is the biologically active
vivo. The (S)-enantiomer is superior to the commercially enantiomer of monastrol, indicating a more potent and
available racemic mixture as a cell biological reagent. specific Eg5 inhibitor. These results will aid in under-
The correlation between the potency of the enantiomers standing the function of Eg5 in vivo and identifying
against Eg5 in vitro and a cellular phenotype supports and characterizing small-molecule inhibitors that tar-
the current understanding of mono-aster formation as get motor proteins.
a result of Eg5 inhibition. The selectivity conferred by
Experimental Proceduresthe chiral center of monastrol suggests that Eg5 inter-
acts with both the dihydropyrimidine and phenol substit-
Materials
uents of monastrol, consistent with our results on the Oligonucleotide primers used in PCR, Ni-NTA resin, and reagents
activities of several monastrol derivatives (our unpub- for DNA purification were obtained from Qiagen. High-purity deoxy-
lished results). ribonucleotide triphosphates were purchased from Boehringer-
Mannheim. Enzymes and buffers for DNA cloning were obtainedDisruption of the energy transfer between mant-
from New England Biolabs. Luria-Bertani media powder was pur-labeled nucleotides and Eg5 is a useful method to mea-
chased from VWR. Isopropyl -D-thiogalacto-pyranoside (IPTG),sure the binding of monastrol and potentially other Eg5
protease inhibitors, buffers, and reagents for agarose gel electro-
inhibitors to the motor domain. The FRET donor is likely phoresis, the NADH enzyme-coupled assay, and the synthesis of
to be tryptophan 127, an amino acid located in the L5 monastrol were purchased from Sigma-Aldrich. Reagents for the
loop of the Eg5 motor domain, close to the nucleotide Bradford protein concentration assay and SDS-PAGE were pur-
chased from BioRad. Microcon-10 concentrators were purchasedbinding pocket [10]. Efficient quenching of FRET sug-
from Amicon, Inc. Reagents for tissue culture were obtained fromgests that monastrol may bind near the L5 loop or nucle-
Mediatech, Inc.otide binding pocket of Eg5.
Monastrol causes a characteristic cellular phenotype Synthesis of Monastrol and Para-Monastrol
and does not inhibit microtubule gliding by conventional We synthesized both compounds using the Biginelli condensation
kinesin [4], suggesting that it is specfic for inhibiting Eg5 in refluxing ethanol with hydrochloric acid as an acid catalyst [21]
and purified the resulting product by liquid chromatography as de-over other kinesin motor proteins. The specifity may be
scribed. Monastrol, ethyl 6-methyl-4-(3-hydroxyphenyl)-2-thioxo-due to a high-affinity drug binding site or to a set of key
1,2,3,4-tetrahydropyrimidine-5-carboxylate, was obtained in 62%residues involved in mechanochemical transduction in
yield with a purity of 99% and 1H-NMR spectrum matching thethe motor domain that are unique to Eg5. Other kinesin published synthesis [18]. A similar procedure was followed for the
motor proteins may have analogous “hot spots” to be preparation of para-monastrol, ethyl 6-methyl-4-(4-hydroxyphenyl)-
targeted by specific small-molecule inhibitors [26]. Iden- 2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate but using
4-hydroxy benzaldehyde, with a yield of 68%. 1H NMR (500 MHz,tification of the monastrol binding site on Eg5 by X-ray
DMSO-d6): 1.11 (t, J  7 Hz, 3H); 2.28 (3H); 4.01 (q, J  7 Hz, 2H);crystallography and further biochemical studies of Eg5
5.06 (d, J  3.5 Hz, 1H); 6.71 (d, J  8 Hz, 2H); 7.01 (d, J  8 Hz,may therefore be useful for the design of small-molecule
2H); 9.41, 9.54, 10.24. Stocks of 200 mM monastrol or para-mon-inhibitors against other kinesin motors.
astrol were prepared by dissolving a known mass of powdered
In order to understand the effect of monastrol on spin- compound in dry DMSO. Aliquots of compound were stored
dles in vivo, it will be necessary to understand how at 20C until use. Monastrol absorbs with absorbance maxima at
monastrol affects the interactions between partner 300 nm and 310 nm in 20 mM potassium PIPES (pH 6.9), 25 mM
potassium chloride, 260  4750 and 310  10,600 used for futureheads in the full-length tetrameric Eg5 complex and
biochemical work.whether there is allosteric communication through the
stalk region that regulates microtubule binding by the
Cloning and Expression of Eg5 Constructscomplex. For example, inhibition of ADP release in one
Coding regions for the expression of C terminally His6-tagged con-
head might preclude microtubule release by a partner structs of human Eg5 were generated by polymerase chain reaction
head, which might cause stalling of Eg5 in a microtubule- using a pBluescript template containing full-length human Eg5 [20]
and the following primers: a common N-terminal primer, 5	-GCAACbound form in the spindle. Future biochemical experi-
Mechanism of Eg5 Inhibition by Monastrol
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GATTAATATGGCGTCGCAGCCAAATTCGTCTGCGAAG, and specific through a 10 kDa MWCO microcon in a tabletop centrifuge, such that
approximately 60 l passed through the membrane. Comparison ofC-teminal primers, 5	-GCAACGCTCGAGTCAGTGATGATGGTGGTG
ATGCTGATTCACTTCAGGCTTATTCAATAT (hEg5-367H), 5	-GCAAC UV spectra of flowthrough solutions from reactions containing Eg5
and those with no protein was used to calculate the amount of ADPGCTCGAGTCAGTGATGATGGTGGTGATGCATGACTCTAAAATTTT
CTTCAGAAAT (hEg5-405H), 5	-GCAACGCTCGAGTCAGTGATGATGG and monastrol retained by Eg5 across the membrane, Fmax to Fmin.
Using ADP solutions of known concentration [24], we determinedTGGTGATGTGTAACCCTATTCAGCTCCTCCTCAACAGC (hEg5-437H).
The PCR products were ligated into a pRSETa backbone. Eg5 pro- that 260 for ADP is 13,200 cm1 under these buffer conditions.
tein constructs were expressed and purified as described previously
[16]. The Eg5 containing fractions from Superose 6 sizing chroma- Separation of Monastrol Enantiomers by Chiral HPLC
tography were pooled, supplemented with sucrose to 10% (w/v) as We resolved the two enantiomers of monastrol by chiral HPLC over
a cryoprotectant, flash frozen in liquid nitrogen, and stored at80C. a Chiracel OD-H column based on the published method [18]. We
The concentration of Eg5 was measured using the Edelhoch [22] verified the enantiomeric purity of our fractions by analytical chiral
as well as Bradford techniques. HPLC under the conditions of our purification, using only fractions
with 99% enantiomeric excess in our biochemical experiments.
Stocks of enantiomerically pure monastrol were prepared by dis-Steady-State Eg5 ATPase Assay
solving concentrated column fractions in fresh DMSO and wereAn enzyme-coupled system that regenerates ADP to ATP is a conve-
stored at 20C until use. Drug concentration was measured by UVnient method to measure ATP hydrolysis by Eg5, with NADH fluores-
absorbance at 310 nm.cence as indirect measure of ATP turnover [16]. Our typical reaction
buffer contained 25 mM potassium chloride, 20 mM potassium
PIPES (pH 6.90), 2 mM magnesium chloride, 1 mM potassium phos- Cell Culture Methods
phoenol pyruvate, 200 M di-potassium NADH, 1 mM dithiothreitol, BS-C-1 cells were cultured as described previously [25]. Cells were
10 M taxol, 9 U/ml lactate dehydrogenase, 1 U/ml pyruvate kinase, grown on glass coverslips to 50% confluence, rinsed with warm
and taxol-stabilized microtubules as needed. To measure the PBS, and incubated an additional 6 hr in growth medium supple-
ATPase activity in a reaction, the assay buffer was supplemented mented with 20 mM potassium HEPES and monastrol derivative at
with appropriate amounts of MgCl2:ATP (1:1), microtubules, and a final DMSO concentration of 0.2%. Cells were crosslinked with
Eg5. Time points for NADH fluorescence were measured in 384-well glutaraldehyde followed by treatment with sodium borohydride.
black plates (NalgeneNUNC) by a Wallac Victor2 1420 multilabel Cells were stained with FITC-conjugated DM-1A, an antibody
counter, umbelliferone filter set (excitation, 355 nm; emission, 420 against 
-tubulin (Sigma), and Hoechst dye. Cells were classified
nm), and the steady-state rate of fluorescence decay was calculated as mono-astral, normal mitotic, interphase, or other by visual inspec-
using a linear fit by Microsoft Excel. The coupling activity of the tion to calculate the percentage of monastral cells at each drug
enzyme system was 100-fold greater than the Eg5 ATPase activity concentration.
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